Bharat [BIBCL] vs OneSource Specialty [ONESOURCE] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Bharat Immunologicals & Biologicals Corporation Limited wins in 3 metrics, OneSource Specialty Pharma Inc. wins in 13 metrics, with 0 ties. OneSource Specialty Pharma Inc. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Bharat Immunologicals & Biologicals Corporation Limited | OneSource Specialty Pharma Inc. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -4.59 | 936.63 | OneSource Specialty Pharma Inc. |
| Price-to-Book Ratio | 0.97 | 3.11 | Bharat Immunologicals & Biologicals Corporation Limited |
| Debt-to-Equity Ratio | 94.48 | 21.93 | OneSource Specialty Pharma Inc. |
| PEG Ratio | -0.08 | 42.24 | OneSource Specialty Pharma Inc. |
| EV/EBITDA | -7.13 | 40.79 | OneSource Specialty Pharma Inc. |
| Profit Margin (TTM) | -241.59% | 1.42% | OneSource Specialty Pharma Inc. |
| Operating Margin (TTM) | -2,888.44% | -18.02% | OneSource Specialty Pharma Inc. |
| Return on Equity | -21.00% | -0.31% | OneSource Specialty Pharma Inc. |
| Return on Assets (TTM) | -6.28% | -0.24% | OneSource Specialty Pharma Inc. |
| Free Cash Flow (TTM) | $108.92M | $-1.96B | Bharat Immunologicals & Biologicals Corporation Limited |
| 1-Year Return | -32.86% | -20.38% | OneSource Specialty Pharma Inc. |
| Price-to-Sales Ratio (TTM) | 9.97 | 13.01 | Bharat Immunologicals & Biologicals Corporation Limited |
| Enterprise Value | $1.42B | $195.90B | OneSource Specialty Pharma Inc. |
| EV/Revenue Ratio | 18.52 | 13.80 | OneSource Specialty Pharma Inc. |
| Gross Profit Margin (TTM) | N/A | 67.50% | N/A |
| Revenue per Share (TTM) | $2 | $124 | OneSource Specialty Pharma Inc. |
| Earnings per Share (Diluted) | $-3.59 | $1.72 | OneSource Specialty Pharma Inc. |
| Beta (Stock Volatility) | 0.34 | N/A | N/A |
Bharat Immunologicals & Biologicals Corporation Limited vs OneSource Specialty Pharma Inc. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Bharat Immunologicals & Biologicals Corporation Limited | 0.71% | -1.61% | -1.38% | 5.28% | -9.50% | -14.68% |
| OneSource Specialty Pharma Inc. | 0.68% | -6.58% | -11.52% | 8.72% | 0.44% | -9.19% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Bharat Immunologicals & Biologicals Corporation Limited | -32.86% | -26.70% | -80.09% | -12.27% | 29.14% | 57.16% |
| OneSource Specialty Pharma Inc. | -20.38% | -5.70% | -5.70% | -5.70% | -5.70% | -5.70% |
Performance & Financial Health Analysis: Bharat Immunologicals & Biologicals Corporation Limited vs OneSource Specialty Pharma Inc.
| Metric | BIBCL | ONESOURCE |
|---|---|---|
| Market Information | ||
| Market Cap | ₹762.99M | ₹202.76B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 35,100 | 1,038,625 |
| 90 Day Avg. Volume | 35,515 | 610,058 |
| Last Close | ₹17.14 | ₹1,623.40 |
| 52 Week Range | ₹14.10 - ₹25.65 | ₹1,057.00 - ₹2,248.00 |
| % from 52W High | -33.18% | -27.78% |
| All-Time High | ₹94.50 (Jun 14, 2021) | ₹2,248.00 (Jun 18, 2025) |
| % from All-Time High | -81.86% | -27.78% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.99% | -0.26% |
| Quarterly Earnings Growth | -1.00% | N/A |
| Financial Health | ||
| Profit Margin (TTM) | -2.42% | 0.01% |
| Operating Margin (TTM) | -28.88% | -0.18% |
| Return on Equity (TTM) | -0.21% | 0.00% |
| Debt to Equity (MRQ) | 94.48 | 21.93 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹18.24 | ₹518.08 |
| Cash per Share (MRQ) | ₹2.07 | ₹14.56 |
| Operating Cash Flow (TTM) | ₹87.48M | ₹-2,152,760,000 |
| Levered Free Cash Flow (TTM) | ₹-166,388,000 | ₹-179,710,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Bharat Immunologicals & Biologicals Corporation Limited vs OneSource Specialty Pharma Inc.
| Metric | BIBCL (Apr 26, 2026) | ONESOURCE (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -4.59 | 936.63 |
| Forward P/E | N/A | 42.24 |
| PEG Ratio | -0.08 | 42.24 |
| Price to Sales (TTM) | 9.97 | 13.01 |
| Price to Book (MRQ) | 0.97 | 3.11 |
| Market Capitalization | ||
| Market Capitalization | ₹762.99M | ₹202.76B |
| Enterprise Value | ₹1.42B | ₹195.90B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 18.52 | 13.80 |
| Enterprise to EBITDA | -7.13 | 40.79 |
| Risk & Other Metrics | ||
| Beta | 0.34 | N/A |
| Book Value per Share (MRQ) | ₹18.24 | ₹518.08 |
Financial Statements Comparison: Bharat Immunologicals & Biologicals Corporation Limited vs OneSource Specialty Pharma Inc.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | BIBCL (2023) | ONESOURCE (2025) |
|---|---|---|
| Revenue/Sales | 446.09M | 14.45B |
| Cost of Goods Sold | 422.08M | 4.35B |
| COGS % of Revenue | 94.6% | 30.1% |
| Gross Profit | 24.01M | 10.10B |
| Gross Margin | 5.4% | 69.9% |
| Research & Development | 0 | 20.49M |
| Operating Income (EBIT) | -160.07M | 1.90B |
| Operating Margin | -35.9% | 13.2% |
| EBITDA | -154.93M | 4.71B |
| EBITDA Margin | -34.7% | 32.6% |
| Pre-Tax Income | -222.68M | -670.66M |
| Pre-Tax Income % of Revenue | -49.9% | -4.6% |
| Income Tax | -56.29M | -497.85M |
| Income Tax % of Revenue | -12.6% | -3.4% |
| Net Income (Profit) | -166.39M | -179.71M |
| Profit Margin | -37.3% | -1.2% |
Balance Sheet & Liquidity Metrics
| Metric | BIBCL (2023) | ONESOURCE (2025) |
|---|---|---|
| Cash & Equivalents | 12.86M | 1.56B |
| Total Current Assets | 358.03M | 10.86B |
| Total Current Assets % of Revenue | 80.3% | 75.2% |
| Total Current Liabilities | 940.42M | 11.14B |
| Total Current Liabilities % of Revenue | 210.8% | 77.1% |
| Long-Term Debt | N/A | 3.83B |
| Long-Term Debt % of Revenue | 0.0% | 26.5% |
| Total Shareholders Equity | 882.14M | 58.81B |
| Retained Earnings | -662.11M | -18.43B |
| Retained Earnings % of Revenue | -148.4% | -127.6% |
| Property, Plant & Equipment | 72.02M | 8.97B |
Cash Flow Statement Comparison
| Metric | BIBCL (2023) | ONESOURCE (2025) |
|---|---|---|
| Operating Cash Flow | 87.48M | -2.15B |
| Operating Cash Flow % of Revenue | 19.6% | -14.9% |
| Capital Expenditures | 0 | N/A |
| Free Cash Flow | 108.92M | -1.96B |
| FCF Margin | 24.4% | -13.6% |
| Debt Repayment | N/A | -6.31B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | BIBCL | ONESOURCE |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 43.18M | 114.64M |
| Float Shares | 17.58M | 70.43M |
| % Held by Insiders | 59.25% | 38.63% |
| % Held by Institutions | 0.00% | 26.67% |
| % Held by Public | 40.75% | 34.70% |
Dividend Analysis & Yield Comparison: Bharat Immunologicals & Biologicals Corporation Limited vs OneSource Specialty Pharma Inc.
| Metric | BIBCL | ONESOURCE |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |